A phase 2 trial of the efficacy and safety of elotuzumab in combination with pomalidomide, carfilzomib and dexamethasone for high-risk relapsed/refractory multiple myeloma
暂无分享,去创建一个
T. Spektor | J. Berenson | R. Swift | David Yashar | R. Vescio | S. Eshaghian | B. Eades | Gary T. Schwartz | Stephen W Lim | D. Martinez | Matthew Ghermezi